TJ-C64B / NovaBridge Biosciences - LARVOL DELTA

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022 (PRNewswire) - "TJ210/MOR210 - Phase 1 clinical trial in patients with advanced solid tumors: The phase 1 study is ongoing in the U.S., and patient recruitment for dose escalation will be completed in Q3 2022. In addition, the clinical study report of this phase 1 study is expected in Q4 2022. The phase 1 clinical trial in Chinese patients has been approved by China NMPA. Currently, no active clinical study is ongoing....TJ-C64B - TJ-C64B is now under pre-clinical development and the Company plans to submit an IND in the U.S. around mid-2023."

IND • P1 data • Trial status • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting (PRNewswire) - "I-Mab...today announced that two poster presentations featuring translational research data of enoblituzumab (also known as TJ271) and preclinical data of TJ-C64B will be presented at the American Association for Cancer Research (AACR) 2022 Annual Meeting, to be held April 8-13, 2022....'We continue to make significant progress in advancing our innovative pipeline to generate the next wave of novel cancer therapeutics for patients around the world,' said Dr. Andrew Zhu...'The translational research data of enoblituzumab provide compelling rationale to further investigate combination therapy for increased clinical efficacy against multiple cancer types. In addition, the preclinical data of TJ-C64B provide the underlying mechanism of action for further clinical development of this novel bispecific antibody."

Media quote • Preclinical

I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting (PRNewswire) - "Data confirmed the immunosuppressive function of B7-H3 and demonstrated the immunoregulatory function of enoblituzumab as evidenced by the activation of cytolytic T cell and NK cells, reinvigoration of exhausted cells, and suppression of M2-like myeloid cells. Enoblituzumab exhibited tumor killing activity against ES-2, a B7-H3-expressing ovarian cancer cell line in vitro....In humanized 4-1BB syngeneic mouse model, TJ-C64B exhibited significant tumor growth inhibition, associated with elevation in tumor infiltrating CD45 and CD8 cells as well as CD8/Treg ratio."

Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor